Symptoms of Parkinson's are the only way to diagnose it. But not for long.

Doctors rely on visible symptoms of Parkinson's to diagnose the disease — ruling out early diagnosis. New research hints at a faster way.

Researchers have discovered a new way to diagnose and track Parkinson’s disease progression — even before the first symptoms of Parkinson’s appear.

Why This Matters

Currently, doctors diagnose Parkinson’s disease after symptoms occur. By that time, there could be significant damage to neurons in some areas of the brain. Earlier diagnosis means people living with Parkinson’s disease could have a better quality of life and save on costly treatments.

There are a wide range of neurodegenerative diseases that are difficult or impossible to diagnose before symptoms occur. This study could also provide new ways for researchers to screen for molecules that could lead to early diagnosis of other diseases like Parkinson’s.

Symptoms of Parkinson’s Are a Limited  Diagnostic Tool

Currently, there are no specific tests for diagnosing Parkinson’s disease. Neurologists look for common symptoms of Parkinson’s, like tremors or changes in speech, and they may use blood tests or genetic tests to rule out other conditions that cause similar symptoms. But the diagnosis of Parkinson’s disease always occurs after the patient already has symptoms.

200,000 people are diagnosed with Parkinson’s in the U.S. each year. Doctors have been looking for new ways to recognize the condition earlier by looking for biological molecules present before symptoms of Parkinson’s become visible. For example, clumps of alpha-synuclein protein commonly form in the brain before outward signs of the disease appear. But there isn’t a reliable way to recognize and track them.

Positron emission tomography (PET) is an imaging technique to help doctors see inside the body. It uses radioactive molecules as tracers for imaging different tissues. For years, a University of Pennsylvania team worked to find a tracer that would light up alpha-synuclein, the hallmark protein of Parkinson’s. If they could find a selective tracer to identify the protein, doctors could use it to diagnose the disease with a PET scan, possibly before the patient experiences the debilitating symptoms of Parkinson’s.

Now, in a study published in Chemical Science, researchers describe a new way to identify these molecules.

How to Find a Needle in a Haystack

When researchers described and published the alpha-synuclein structure, the team was finally able to experimentally confirm where tracer molecules could bind to the protein. Using a computation method, they screened millions of candidate molecules to see which ones could attach to the protein. They compared their hypothetical molecules’ results to commercially available molecules to find ones with a similar structure to narrow their list down.

They started the process with 7 million potential compounds, narrowed it down to 20 promising candidates that they could test in the lab, and ultimately found two that had a high binding rate to alpha-synuclein.

This proof-of-concept for the process will allow them to quickly design and discover molecules for other neurodegenerative disorders, too.

“This can be something that takes 10 to 15 years in industry, and we’re trying to do it in about five,” says chemist E. James Petersson, lead author on the study.

“I really see this as being a game-changer on how we do PET probe development,” says researcher Robert Mach. “The significance is that we’re able to screen millions of compounds within a very short period of time, and we’re able to identify large numbers of compounds that will likely bind with high affinity to alpha-synuclein.”

We’d love to hear from you! If you have a comment about this article or if you have a tip for a future Freethink story, please email us at [email protected].

New drug for fatty liver disease cuts fat by 65%
A new NASH treatment, efruxifermin, significantly reduced liver fat when combined with a GLP-1 drug in a small trial.
Lung cancer drug slashes patients’ risk of death by 51%
Osimertinib, an FDA-approved lung cancer drug, slashes the risk of death for certain patients by 51%, according to new trial results.
The placenta may play a role in the genetic risk of schizophrenia
Researchers at Johns Hopkins have found that genes associated with schizophrenia risk may impact the placenta, not just the brain.
Gain-of-function research is more than just tweaking risky viruses
Gain-of-function experiments in the lab can help researchers get ahead of viruses naturally gaining the ability to infect people in the wild.
Up Next
Subscribe to Freethink for more great stories